Company / R&D Expense
Edwards Lifesciences R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.1B
FY2025
5-year range
$843.6M / $1.1B
FY2021-FY2025
Trend
+2.5%
vs FY2024
Sector context
#10 of 110
Health Care
What the data says
Among 110 Health Care companies, Edwards Lifesciences is in the top 9% for r&d expense. R&D Expense has increased for 3 consecutive years, from $844M in FY2022 to $1.1B in FY2025.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +7.2%. Top quartile in the Health Care sector.
Improved from $903M to $1.1B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +8.6%
- 5-Year CAGR
- +7.2%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 110This company $1.1B Sector average $298.2M
▼
+261.9% above sector average
Key checks
Key Insights
- Edwards Lifesciences's r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +7.2%, indicating consistent growth.
- In FY2025, r&d expense increased 2.5% year-over-year.
- Ranks #10 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | +2.5% |
| FY2024 | $1.1B | +16.6% |
| FY2023 | $903.1M | +7.1% |
| FY2022 | $843.6M | -6.6% |
| FY2021 | $903.1M | +18.7% |
| FY2020 | $760.7M | +1.1% |
| FY2019 | $752.7M | +21.0% |
| FY2018 | $622.2M | +12.6% |
| FY2017 | $552.6M | +25.0% |
| FY2016 | $442.2M | +15.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026